NCT07878156RecruitingPhase 3
Dexmedetomidine Use for Greater Occipital Nerve Block in Pediatric Posterior Fossa Tumor Surgery.
Dexmedetomidine as an Adjuvant for Ultrasound Guided Greater Occipital Nerve Block in Children Undergoing Posterior Fossa Tumor: A Prospective Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate the effects of ultrasound-guided versus blind greater occipital nerve block (GONB), with or without Dexmedetomidine as an adjuvant, in pediatric patients undergoing posterior fossa tumor excision under general anesthesia. The main questions it aims to answer are: * Does ultrasound-guided GONB improve hemodynamic stability compared with the blind technique? * Does adding dexmedetomidine to GONB affect intraoperative and postoperative opioid consumption, postoperative pain control, and the time to first rescue analgesia? Researchers will compare four groups to evaluate the effects of the nerve block technique and the addition of dexmedetomidine: Group A: Blind GONB using 0.25% bupivacaine. Group B: Blind GONB using 0.25% bupivacaine with dexmedetomidine (1 μg/kg). Group C: Ultrasound-guided GONB using 0.25% bupivacaine. Group D: Ultrasound-guided GONB using 0.25% bupivacaine with dexmedetomidine (1 μg/kg). Participants will be pediatric patients scheduled for elective posterior fossa tumor excision at Children's Cancer Hospital Egypt (CCHE 57357). They will be randomly assigned to one of the four groups and will receive standardized general anesthesia and bilateral GONB according to their assigned group. Intraoperative heart rate and blood pressure, intraoperative and postoperative opioid consumption, and time to first postoperative rescue analgesia will be assessed.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 260 (estimated)
- First submitted
- 10 Oct 2026
- Start date
- 17 Dec 2025
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Children's Cancer Hospital Egypt 57357
- Diseases
- Childhood cancers
- NCT number
- NCT07878156
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 260
- From 17 Dec 2025 to the primary completion date, 30 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Hemodynamic instability prior induction.
Other illness
- Allergy to study drugs (Bupivacaine - Dexmedetomidine)
- Local infection at the site of injection.
Other
- Coagulopathy or use of anticoagulants.
- Pre-existing neurologic deficits that interfere with postoperative pain assessment.
- Developmental delay preventing appropriate pain evaluation.
Who the study is looking for
- Pediatric patient undergoing elective posterior fossa tumor excision.
- ASA physical status II-III.
- Informed consent obtained from parents or legal guardians.
Age in the registry: - to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Children's cancer hospital 57357 Coordinator of this site? Confirm its status | Cairo | Egypt | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.